Atland Pharmace Patent-Cliff Exposure & CMS Drug Spending Portfolio

Atland Pharmace (US): 3 reconciled FDA prescription therapies, $12.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$12.6M
2024 Medicare Part D Spend$3.9M
2024 Medicaid Spend$8.7M
California HCAI SB 17 Filings2 WAC filings (max 52.3% 2-yr change)